Results 1 to 10 of about 15,173,813 (175)
Factor XI Inhibitors: A New Horizon in Anticoagulation Therapy [PDF]
Cardiology and TherapyAnticoagulation therapy has undergone significant evolution, marked by the emergence of direct oral anticoagulants with distinct advantages. Despite these advancements, challenges persist in managing residual thrombotic and bleeding risks, particularly ...
João Presume +2 more
doaj +3 more sources
Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives
Romanian Journal of Internal Medicine, 2023 Factor XI is a zymogen with an important role in the coagulation cascade. It is activated by FXII, thrombin and or it can be autoactivated. It has a prothrombotic effect after being activated by thrombin, but also through its antifibrinolytic action ...
Vlădăreanu Ana-Maria, Roşca Adrian
doaj +3 more sources
Hematology/Oncology Clinics of North America, 2021 Factor XI (FXI) deficiency (hemophilia C or Rosenthal disease) was first described in the 1950s in a multigenerational family experiencing bleeding related to surgery and dental procedures.
M. Lewandowska, J. Connors
semanticscholar +3 more sources
Einstein (São Paulo), 2004 We describe a patient with a prolonged aPTT who was diagnosedas having factor XI deficiency after a rather large hematoma wasformed after angiography.
Jayme Diamant +4 more
doaj +3 more sources
XI before X: The Promise of Factor XI Inhibitors [PDF]
Kidney International ReportsJeffrey I. Weitz, Husam Alzayer
doaj +4 more sources
Case Report: Allelic and biallelic variants in coagulation factor XI cause factor XI deficiency [PDF]
Frontiers in Cardiovascular MedicineFactor XI deficiency is a rare inherited coagulation disorder with an estimated prevalence of affecting 1 in 1 million. It is characterized by mild and variable bleeding phenotypes, including bruises, nosebleeds, hematuria, and postpartum hemorrhage.
Chen Liang +9 more
doaj +2 more sources
Factor XI and XII inhibitors–Dawn of a new era [PDF]
Indian Heart JournalThe history of coagulation cascade dates back to 17th century. The extrinsic and intrinsic pathways were proposed in 1998. Extrinsic pathway includes the tissue factor and stable factor which activates factor X and with help of factor V, this converts ...
Chhabi Satpathy +2 more
doaj +2 more sources
Factor XI localization in human deep venous thrombus and function of activated factor XI on venous thrombus formation and hemostasis [PDF]
Research and Practice in Thrombosis and HaemostasisBackground: Novel anticoagulants targeting coagulation factor (F)XI/activated FXI (FXIa) are currently under development. However, whether FXI is present in human deep vein thrombosis (DVT) and whether FXIa and activated FX (FXa) play different roles in ...
Nobuyuki Oguri +12 more
doaj +2 more sources
Factor XI Deficiency in apoE/FXI Double-Knockout Mice Decreases Atherosclerosis by Lowering MSR1 mRNA Expression Within the Plaque [PDF]
Journal of Lipid and AtherosclerosisObjective Atherosclerosis remains a leading cause of global morbidity and mortality despite cholesterol-lowering drugs and risk factor management. In mice, the absence of coagulation factor XI (FXI) on an apolipoprotein E (apoE)−/− genetic background ...
Reut Shnerb Ganor +12 more
doaj +2 more sources
Targeting factor XI as a compromise between thrombosis and bleeding [PDF]
Cardiology JournalThromboembolic diseases have long been a leading cause of morbidity and mortality, necessitating advances in anticoagulant drugs. Heparins, vitamin K inhibitors, and direct oral anticoagulants (DOACs) are well-established drug classes that help prevent ...
Aleksandra Żuk-Łapan +6 more
doaj +2 more sources